918博天堂(中华区)官方网站

Huaota is pleased to announce that the company has received the Clinical Trial Approval in respect of Project HB002.1T issued by the National Medical Products Administration (NMPA) for treatment of advanced solid tumors. HB002.1T is a fusion protein of recombinant human vascular endothelial growth factor (VEGF) receptor and Fc fraction of human IgG targeting VEGF.